Cited by 562Cytokine Signaling Pathways and InteractionsLung Cancer Treatments and MutationsMelanoma and MAPK Pathways

The DOI matches its Crossref record; 39 of the 40 references it cites were found in a registry or an index.

Drug Resistance via Feedback Activation of Stat3 in Oncogene-Addicted Cancer Cells

Open access

Lee, Ho-June, Zhuang, Guanglei, Cao, Yi, Du, Pan, Kim, Hyo-Jin, Settleman, Jeff·2014·Cancer Cell

DOI 10.1016/j.ccr.2014.05.019

Open this paper in CoChat — free account Open PDF

Abstract

Pathway-targeted cancer drugs can produce dramatic responses that are invariably limited by the emergence of drug-resistant cells. We found that many drug-treated "oncogene-addicted" cancer cells engage a positive feedback loop leading to Stat3 activation, consequently promoting cell survival and limiting overall drug response. This was observed in cancer cells driven by diverse activated kinases, including EGFR, HER2, ALK, and MET, as well as mutant KRAS. Specifically, MEK inhibition led to autocrine activation of Stat3 via the FGF receptor and JAK kinases, and pharmacological inhibition of MEK together with JAK and FGFR enhanced tumor regression. These findings suggest that inhibition of a Stat3 feedback loop may augment the response to a broad spectrum of drugs that target pathways of oncogene addiction.

Integrity signals

Registry

Crossref · 10.1016/j.ccr.2014.05.019

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Differential expression analysis for sequence count data
Anders, S., & Huber, W. (2010) · Genome Biology · doi:10.1186/gb-2010-11-10-r106 · Cited by 15,581
Linear Models and Empirical Bayes Methods for Assessing Differential Expression in Microarray Experiments
Smyth, G. K. (2004) · Statistical Applications in Genetics and Molecular Biology · doi:10.2202/1544-6115.1027 · Cited by 11,829
Glioma stem cells promote radioresistance by preferential activation of the DNA damage response
Bao, S., Wu, Q., McLendon, R. E., Hao, Y., Shi, Q., Hjelmeland, A. B., Dewhirst, M. W., Bigner, D. D., & Rich, J. N. (2006) · Nature · doi:10.1038/nature05236 · Cited by 6,363
Cancer drug resistance: an evolving paradigm
Holohan, C., Van Schaeybroeck, S., Longley, D. B., & Johnston, P. G. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3599 · Cited by 4,681
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
STATs in cancer inflammation and immunity: a leading role for STAT3
Yu, H., Pardoll, D., & Jove, R. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2734 · Cited by 4,383
An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients
Györffy, B., Lanczky, A., Eklund, A. C., Denkert, C., Budczies, J., Li, Q., & Szallasi, Z. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0674-9 · Cited by 4,169
Epidermal growth factor receptor mutations in lung cancer
Sharma, S. V., Bell, D. W., Settleman, J., & Haber, D. A. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2088 · Cited by 3,170
Self-citation
Stat3 as an Oncogene
Bromberg, J. F., Wrzeszczynska, M. H., Devgan, G., Zhao, Y., Pestell, R. G., Albanese, C., & Darnell, J. E. (1999) · Cell · doi:10.1016/s0092-8674(00)81959-5 · Cited by 2,790
A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
Sharma, S. V., Lee, D. Y., Li, B., Quinlan, M. P., Takahashi, F., Maheswaran, S., McDermott, U., Azizian, N., Zou, L., Fischbach, M. A., et al. (2010) · Cell · doi:10.1016/j.cell.2010.02.027 · Cited by 2,770
Self-citation

Flagged first, then by citations

Show all 40 references

1 of the 40 references couldn’t be matched to a known paper.

Sorted by citations

Items 501–562 of 562

Adenocarcinoma of the lung: an exploration of the relationships between histopathology, molecular pathology and inflammatory markers and their relationship to patient outcomes
Clay, T. D. (2017) · Minerva Access (University of Melbourne)
Understanding the Biology Behind the EGFR to Improve NSCLC Patients’ Treatment
Verlicchi, A., & Addeo, A. (2017) · Journal of Molecular and Genetic Medicine · doi:10.4172/1747-0862.1000286
Combinations of Genomically and Immune-Targeted Therapies in Early-Phase Clinical Trials
Patel, M. R., Patel, S. P., & Kurzrock, R. (2017) · Current cancer research · doi:10.1007/978-3-319-63757-0_9
Microenvironmental Regulation of Tumor Resistance to Anti-IGF-1R Monoclonal Antibody
이지선 (2017) · Seoul National University Open Repository (Seoul National University)
Multiscale Stochastic Modeling Connects Cancer Drug Resistance Mechanisms to Population Survival Rates
Sun, X. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.76185
In the literature: April 2019
Bruxiola, G., Cejalvo, J. M., Gambardella, V., & Cervantes, A. M. R. (2019) · ESMO Open · doi:10.1136/esmoopen-2019-000513
STAT3β is a tumor suppressor in acute myeloid leukemia
Aigner, P. (2019) · Intrinsic Activity · doi:10.25006/ia.7.s1-a3.3
RPPAs for Cell Subpopulation Analysis
Kume, K., & Nishizuka, S. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-981-32-9755-5_12
Quinacrine binds to the kinase domain of FGFR1 and inhibits its activityPreprint
Kumar, M., & Sarkar, A. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.12.02.470934
Data from MET-Induced CD73 Restrains STING-Mediated Immunogenicity of EGFR-Mutant Lung Cancer
Yoshida, R., Saigí, M., Tani, T., Springer, B. F., Shibata, H., Kitajima, S., Mahadevan, N. R., Campisi, M., Kim, W., Kobayashi, Y., et al. (2023) · doi:10.1158/0008-5472.c.6514215.v1
Data from Adaptive Resistance to Dual BRAF/MEK Inhibition in BRAF-Driven Tumors through Autocrine FGFR Pathway Activation
Wang, V. E. H., Xue, J. Y., Frederick, D. T., Cao, Y., Lin, E., Wilson, C., Urisman, A., Carbone, D. P., Flaherty, K. T., Bernards, R., et al. (2023) · doi:10.1158/1078-0432.c.6527784
Self-citation
Data from InsR/IGF1R Pathway Mediates Resistance to EGFR Inhibitors in Glioblastoma
Ma, Y., Tang, N., Thompson, R. C., Mobley, B. C., Clark, S. W., Sarkaria, J. N., & Wang, J. (2023) · doi:10.1158/1078-0432.c.6524027.v1
Application of Nano-Antibodies for Cancer Immunotherapy
Singh, S., Singh, S. P., & Parihar, A. S. (2023) · Current Tissue Microenvironment Reports · doi:10.1007/s43152-023-00044-z
Transcription Factors in Cancer
Alsiary, R., Albukhari, T. A., & Filimban, W. A. (2023) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9789815080384123010010
Dissecting fibroblast growth factor-induced endocrine therapy resistance in breast cancer cellsPreprint
Altelaar, M. A. F., Veth, T. S., & Piskopou, A. (2023) · Research Square · doi:10.21203/rs.3.rs-3075627/v1
Coordinative Activities of STAT3 Inhibitor BP-1-102 and Sorafenib Against Proliferation, Angiogenesis and EMT in Hepatocellular CarcinomaPreprint
Zhang, H., Wang, Z., Yu, J., Yan, M., Xiao, W., & Li, J. (2023) · Research Square · doi:10.21203/rs.3.rs-3264321/v1
Cellular Response to an Act of Surviving Drives Tumor Evolution and Tumor HeterogeneityPreprint
Zhang, Y. (2023) · Preprints.org · doi:10.20944/preprints202310.1417.v1
WITHDRAWNPreprint
Zhang, Y. (2023) · doi:10.31219/osf.io/6qp2v
Cellular Response to an Act of Surviving Drives Tumor Evolution and Tumor HeterogeneityPreprint
Zhang, Y. (2023) · Preprints.org · doi:10.20944/preprints202310.1417.v2
The CCL2-CCR2 axis contributes to acquired osimertinib resistance in lung cancer by upregulating Zeb1 expressionPreprint
Chang, T., Tsai, M., Wu, S., Liu, Y.-N., Wu, H., Tsai, T.-H., Lu, P.-H., Jheng, H.-N., Hsu, C., Yeh, P.-S., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-3674324/v1
Additional file 6 of Secondary resistance to anti-EGFR therapy by transcriptional reprogramming in patient-derived colorectal cancer models
Vangala, D., Ladigan, S., Liffers, S. T., Noseir, S., Maghnouj, A., Götze, T.-M., Verdoodt, B., Klein‐Scory, S., Godfrey, L., Zowada, M. K., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14998919
Additional file 1 of Essential role for STAT3/FOXM1/ATG7 signaling-dependent autophagy in resistance to Icotinib
Lyu, X., Zeng, L., Shi, J., Ming, Z., Li, W., Liu, B., Chen, Y., Yuan, B., Sun, R., Yuan, J., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20056597
Additional file 1 of Secondary resistance to anti-EGFR therapy by transcriptional reprogramming in patient-derived colorectal cancer models
Vangala, D., Ladigan, S., Liffers, S. T., Noseir, S., Maghnouj, A., Götze, T.-M., Verdoodt, B., Klein‐Scory, S., Godfrey, L., Zowada, M. K., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14998901
Additional file 3 of Secondary resistance to anti-EGFR therapy by transcriptional reprogramming in patient-derived colorectal cancer models
Vangala, D., Ladigan, S., Liffers, S. T., Noseir, S., Maghnouj, A., Götze, T.-M., Verdoodt, B., Klein‐Scory, S., Godfrey, L., Zowada, M. K., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14998910
Additional file 7 of Secondary resistance to anti-EGFR therapy by transcriptional reprogramming in patient-derived colorectal cancer models
Vangala, D., Ladigan, S., Liffers, S. T., Noseir, S., Maghnouj, A., Götze, T.-M., Verdoodt, B., Klein‐Scory, S., Godfrey, L., Zowada, M. K., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14998925
Additional file 5 of Secondary resistance to anti-EGFR therapy by transcriptional reprogramming in patient-derived colorectal cancer models
Vangala, D., Ladigan, S., Liffers, S. T., Noseir, S., Maghnouj, A., Götze, T.-M., Verdoodt, B., Klein‐Scory, S., Godfrey, L., Zowada, M. K., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14998916
Additional file 4 of Secondary resistance to anti-EGFR therapy by transcriptional reprogramming in patient-derived colorectal cancer models
Vangala, D., Ladigan, S., Liffers, S. T., Noseir, S., Maghnouj, A., Götze, T.-M., Verdoodt, B., Klein‐Scory, S., Godfrey, L., Zowada, M. K., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14998913
Anti-cancer Potential of Farrerol Against Esophageal Carcinoma via Inhibiting STAT3-EGFR Signaling Pathway
Bai, Y., Zhang, T., Hussain, S. A., Alrubie, T. M., & Long, F. (2024) · Revista Brasileira de Farmacognosia · doi:10.1007/s43450-024-00596-7
Heterogeneidad tumoral: la próxima frontera
Arrieta, O. G., Cabrera, L., Dávila, D., Ruíz-Patiño, A., & Cardona, A. F. (2024) · Medicina · doi:10.56050/01205498.2370
Cryptotanshinone differentially induces cell death in ATP6V0D1-deficient pancreatic cancer cells
Chen, F., Lin, J., Cai, X., Tang, H., Li, S., Liang, R., Kang, R., Zhang, Z., Tang, D., & Liu, J. (2025) · Cancer Drug Resistance · doi:10.20517/cdr.2025.103
Comprehensive miRNA profiles revealing cancer-immunityPreprint
Yin, J., zhou, Y., Chang, Z., Yu, J., Wang, C., Qian, Z., Liu, Z., Wang, G., & Ding, N. (2025) · Research Square · doi:10.21203/rs.3.rs-7430586/v1
Targeting dual-specificity phosphatase 23 to overcome chemoresistance and stem cell-like behavior in non-small cell lung cancer cells
Keum, S., Hwang, Y., Lee, M., Song, S., Jeong, J., Hwang, Y. E., Choi, J., Kim, J. W., & Rhee, S. (2025) · Scientific Reports · doi:10.1038/s41598-025-24452-3
Additional file 1 of Intravesical instillation-based mTOR-STAT3 dual targeting for bladder cancer treatment
Lee, D. H., Yoo, J. K., Um, K. H., Ha, W., Lee, S. M., Park, J., Kye, M. J., Suh, J., & Choi, J. W. (2024) · Figshare · doi:10.6084/m9.figshare.26054692
Additional file 2 of Secondary resistance to anti-EGFR therapy by transcriptional reprogramming in patient-derived colorectal cancer models
Vangala, D., Ladigan, S., Liffers, S. T., Noseir, S., Maghnouj, A., Götze, T.-M., Verdoodt, B., Klein‐Scory, S., Godfrey, L., Zowada, M. K., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14998907
Additional file 4 of Targeting IGF1R signaling enhances the sensitivity of cisplatin by inhibiting proline and arginine metabolism in oesophageal squamous cell carcinoma under hypoxia
Fang, K., Sun, M., Leng, Z., Chu, Y., Zhao, Z., Li, Z., Zhang, Y., Xu, A., Zhang, Z., Zhang, L., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22617799
Additional file 2 of Targeting IGF1R signaling enhances the sensitivity of cisplatin by inhibiting proline and arginine metabolism in oesophageal squamous cell carcinoma under hypoxia
Fang, K., Sun, M., Leng, Z., Chu, Y., Zhao, Z., Li, Z., Zhang, Y., Xu, A., Zhang, Z., Zhang, L., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22617793
Additional file 1 of Edible and cation-free kiwi fruit derived vesicles mediated EGFR-targeted siRNA delivery to inhibit multidrug resistant lung cancer
Huang, H., Yi, X., Wei, Q., Li, M., Cai, X., Lv, Y., Weng, L., Mao, Y., Fan, W., Zhao, M., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26566451
Additional file 3 of Targeting IGF1R signaling enhances the sensitivity of cisplatin by inhibiting proline and arginine metabolism in oesophageal squamous cell carcinoma under hypoxia
Fang, K., Sun, M., Leng, Z., Chu, Y., Zhao, Z., Li, Z., Zhang, Y., Xu, A., Zhang, Z., Zhang, L., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22617796
Additional file 1 of Targeting IGF1R signaling enhances the sensitivity of cisplatin by inhibiting proline and arginine metabolism in oesophageal squamous cell carcinoma under hypoxia
Fang, K., Sun, M., Leng, Z., Chu, Y., Zhao, Z., Li, Z., Zhang, Y., Xu, A., Zhang, Z., Zhang, L., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22617790
Stratified signaling network remodeling of kinase–transcription factors’ interactions in Parkinson’s disease
Zhou, X., Parisi, L., Liu, S., Cheng, Z., Liang, H., Youseffi, M., Javid, F. A., & Ma, R. (2026) · Bioinformatics Advances · doi:10.1093/bioadv/vbag059
KDM6B promotes VEGFA expression and vasculogenic mimicry in glioblastoma cells under hypoxia conditions
Zhou, J., Li, L., Zhang, Y., Ma, X., Guo, X., & Sui, A. (2026) · Experimental Brain Research · doi:10.1007/s00221-026-07257-2
AI-assisted systems pharmacology with experimental validation reveal multi-target anticancer mechanisms of Ganoderma lucidum extracts against lung cancer
Wang, H., Chen, L., Zhang, S., Ju, M., Feng, J., Tang, Z., Li, J., El-Seedi, H. R., & Wang, Y. (2026) · Mycology: An International Journal on Fungal Biology · doi:10.1080/21501203.2026.2634522
CD59 promotes pancreatic cancer progression via a tumor cell-intrinsic JAK2-STAT3 signaling axis
Li, Z., Chen, X., wu, Y., & Xu, Y. (2026) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2026.153609
A monoterpenoid dihydrochalcone derivative isolated from Conamomum rubidum sensitizes erlotinib-mediated lung cancer cell death by suppressing STAT3/Bcl-2 signaling
Iksen, I., Jitsayreerat, C., Klanbunchum, C., Nguyen, H. M., Hoang, H. N. T., Hồ, Đ. V., & Pongrakhananon, V. (2026) · Medicine in Drug Discovery · doi:10.1016/j.medidd.2026.100254
Identification of APOBEC-Associated Frequent Mutations and Characterization of FGFR3-Driven Signaling Pathways in Bladder Cancer
Shi, M. (2019) · theses.fr (ABES) · doi:10.70675/3635da7az5e15z4aaaz890cz02e6ace799ec
Notch activation upon DNA damage : molecular characterisation and therapeutic applications in lung adenocarcinoma
Bernardo, S. (2019) · theses.fr (ABES) · doi:10.70675/df87afcbz5843z4c32z9d7cz074065a8acf1
Rôle de la protéine RICTOR dans le développement des mélanomes
Jebali, A. (2020) · theses.fr (ABES) · doi:10.70675/468ac338zaceaz4caaza391zda7d8da0cb2a
Molecular mechanisms of drug-tolerance to EGFR-targeted therapies in lung adenocarcinoma
Léonce, C. (2021) · theses.fr (ABES) · doi:10.70675/0611e924z7044z428cz90dcz9235e0a4b5a2
ERK1/2 hijack STAT3 via Thr714 phosphorylation to suppress gene expression
Liu, J., Hao, Y., Yu, H., Peng, T., Lu, X. B., Chinn, Y. E., & Yue, J. (2026) · Cell Communication and Signaling · doi:10.1186/s12964-026-02818-y
Deulorlatinib (TGRX-326) in ALK Gene Fusion Positive NSCLC After Failure of Second-Generation Inhibitors: A Single-Arm, Multicenter, Phase 2 Trial
Huang, J., Chen, G., Wang, Z., Jin, W., Zhao, Y., Zhang, Y., Zhuang, W., Xin, Y., Yan, W., Zhou, J., et al. (2026) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2026.103737
Elevated Expression of MALAT1 Contributes to the Survival of Drug-Tolerant Persister Cells Following Targeted Therapy in Lung AdenocarcinomaPreprint
Davis, W. J. H., Thompson, M., Farry, S. M., McKinney, C., Gimenez, G., Hatley, M. E., Kumar, R., Rodger, E. J., Chatterjee, A., Diermeier, S. D., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.07.723110
MiR-23c Regulates the Resistance to Gefitinib in EGFR Mutant Non-Small-Cell Lung Cancer Cells
Ignoto, B., Parisi, I. A., Roma, C., Camerlingo, R., Dotolo, S., Tufano, S., Maiello, M. R., Normanno, N., Morabito, A., Luca, A. D., et al. (2026) · Cells · doi:10.3390/cells15121043
M1C IS NECESSARY FOR DARAXONRASIB RESISTANCE OF NSCLC KRAS(G12C) MUTANT CELLSPreprint
Takamori, S., Haratake, N., Nonaka, K., Moriya, M., Bhattacharya, A., Takenaka, T., Yoshizumi, T., Long, M. D., & Kufe, D. W. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.06.20.733526
Circular RNAs regulate signal transducer and activator of transcription 3 signaling pathway to drive cancer therapy resistance
Almouh, M., Al-Daoud, F., Jnaid, F., Dabbagh, A., Naef, H., Maarouf, O., & Kassouha, M. (2026) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2026.154291
JI017 Sensitizes EGFR-T790M NSCLC to Erlotinib by Extinguishing the STAT3–Survivin Axis
Kim, D., Kim, Y.-H., Choi, G., Cheon, C., & Ko, S. (2026) · Integrative Cancer Therapies · doi:10.1177/15347354261475694
HER2 targeted therapy resistance in breast cancer: from molecular landscape to clinical aspects
Zhang, H., Ma, D., Li, F., Shao, Z., & Chen, C. (2026) · Science China Life Sciences · doi:10.1007/s11427-025-3311-5
KRAS inhibition drives adaptive surfaceome remodeling and reveals ALPP/ALPPL2 as a targetable vulnerability in pancreatic cancerPreprint
DeLiberty, J. M., Kong, F. Y., Yu, Q., Sindoni, N., Lin, J., Kang, K., Kim, E. Y., Chen, S., Padhye, A., Coker, O., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.10.01.756025
BindingDB Entry 50018463: Allosteric inhibitors of the STAT3 signaling pathway.
BindingDB (2024) · UC San Diego · doi:10.7270/q2m90dwx
BindingDB Entry 50012646: NO-releasing STAT3 inhibitors suppress BRAF-mutant melanoma growth.
BindingDB (2022) · UC San Diego · doi:10.7270/q2m330gn
BindingDB Entry 50015640: Development of Alectinib-Based PROTACs as Novel Potent Degraders of Anaplastic Lymphoma Kinase (ALK).
BindingDB (2023) · UC San Diego · doi:10.7270/q2g164r3
BindingDB Entry 50014097: Structure-based discovery of potent and selective small-molecule inhibitors targeting signal transducer and activator of transcription 3 (STAT3).
BindingDB (2022) · UC San Diego · doi:10.7270/q2pg1wjz
BindingDB Entry 50002075: Chemically Induced Degradation of Anaplastic Lymphoma Kinase (ALK).
BindingDB (2020) · UC San Diego · doi:10.7270/q2xs5xzj

Authors: Lee, H.-J., Zhuang, G., Cao, Y., Du, P., Kim, H.-J., & Settleman, J.
Affiliations: Genentech (US)
Corresponding author: Settleman, Jeff
ORCID: Lee, Ho-June
Zhuang, Guanglei
Cao, Yi
Du, Pan
Venue: Cancer Cell
Publisher: Elsevier BV
Published: 2014-08
Volume: 26
Issue: 2
Pages: 207-221
ISSN: 1535-6108 (ISSN-L)
DOI: 10.1016/j.ccr.2014.05.019
OpenAlex: W2102365935
Cited by: 555
References: 40
Citations by year: 2026: 23 · 2025: 27 · 2024: 36 · 2023: 41 · 2022: 38 · 2021: 61 · 2020: 55 · 2019: 63 · 2018: 46 · 2017: 65 · 2016: 54 · 2015: 42 · 2014: 4
FWCI: 26.52
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 375 d)
Locations: Cancer Cell (publishedVersion)
PubMed (publishedVersion)
Topics: Life Sciences › Immunology and Microbiology › Immunology › Cytokine Signaling Pathways and Interactions
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
Keywords: STAT3, drug resistance, oncogene addiction, positive feedback loop, MEK inhibition, JAK inhibition, fibroblast growth factor receptor, EGFR, HER2, anaplastic lymphoma kinase, MET, mutant KRAS, autocrine signaling, combination therapy, tumor regression
MeSH terms: Erlotinib Hydrochloride, Adenocarcinoma of Lung, Adenocarcinoma, Animals, Antineoplastic Agents, Cell Survival, Humans, Imidazoles, Lung Neoplasms, Mutation, Nitriles, Oncogenes, Proto-Oncogene Proteins, Pyrazoles, Pyridazines, Pyrimidines, Quinazolines, Signal Transduction, Interleukin-6, Proto-Oncogene Proteins p21(ras), Mice, SCID, Receptors, Fibroblast Growth Factor, ras Proteins, Drug Resistance, Neoplasm, Phosphatidylinositol 3-Kinases, Xenograft Model Antitumor Assays, Cell Line, Tumor, STAT3 Transcription Factor, Mice, Kaplan-Meier Estimate, Janus Kinase 1, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Drug Resistance via Feedback Activation of Stat3 in Oncogene-Addicted Cancer Cells

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks